ECSP22049014A - Variantes de progranulina - Google Patents

Variantes de progranulina

Info

Publication number
ECSP22049014A
ECSP22049014A ECSENADI202249014A ECDI202249014A ECSP22049014A EC SP22049014 A ECSP22049014 A EC SP22049014A EC SENADI202249014 A ECSENADI202249014 A EC SENADI202249014A EC DI202249014 A ECDI202249014 A EC DI202249014A EC SP22049014 A ECSP22049014 A EC SP22049014A
Authority
EC
Ecuador
Prior art keywords
progranulin
variants
proteins
ftd
polypeptide
Prior art date
Application number
ECSENADI202249014A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Ray L Y Low
Gerald Maxwell Cherf
Ankita Srivastava
Katrina W Lexa
Rachel Prorok
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of ECSP22049014A publication Critical patent/ECSP22049014A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente variantes de progranulina y prote?nas de fusi?n que comprenden una variante de progranulina y un polip?ptido Fc. Tambi?n se proporcionan en la presente m?todos para el uso de dichas prote?nas para el tratamiento de trastornos asociados con la progranulina (por ejemplo, una enfermedad neurodegenerativa, tal como demencia frontotemporal (FTD)).
ECSENADI202249014A 2019-12-23 2022-06-21 Variantes de progranulina ECSP22049014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962953099P 2019-12-23 2019-12-23
US202063091819P 2020-10-14 2020-10-14

Publications (1)

Publication Number Publication Date
ECSP22049014A true ECSP22049014A (es) 2022-07-29

Family

ID=74184961

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249014A ECSP22049014A (es) 2019-12-23 2022-06-21 Variantes de progranulina

Country Status (4)

Country Link
CL (1) CL2022001712A1 (es)
EC (1) ECSP22049014A (es)
TW (1) TW202138384A (es)
WO (1) WO2021133907A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
WO2025051953A1 (en) * 2023-09-07 2025-03-13 Novo Nordisk A/S Sortilin-1 binders, constructs and uses thereof
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210284701A1 (en) * 2016-07-14 2021-09-16 Emory University Granulin Compositions and Uses Related Thereto
EP3583118B1 (en) 2017-02-17 2025-06-11 Denali Therapeutics Inc. Transferrin receptor transgenic models
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados

Also Published As

Publication number Publication date
CL2022001712A1 (es) 2023-03-24
WO2021133907A1 (en) 2021-07-01
TW202138384A (zh) 2021-10-16

Similar Documents

Publication Publication Date Title
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
CO2022008648A2 (es) Variantes de progranulina
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
ECSP22049014A (es) Variantes de progranulina
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
SA520411662B1 (ar) بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم
MX378790B (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
CR20190480A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
ZA202005875B (en) Lfa3 variants and compositions and uses thereof
AR115565A1 (es) Proteínas de fusión que comprenden progranulina
EA202190062A1 (ru) Слитые белки, содержащие програнулин
AR120892A1 (es) Variantes de progranulina
AR119984A1 (es) Proteínas de fusión nkg2d y sus usos
AR114938A1 (es) Variantes de expresión de cdkl5 y proteínas de fusión cdkl5
UA115420U (xx) Спосіб відновлення деталей